Literature DB >> 2743817

Determination of the breakpoints of 1;7 translocations in myelodysplastic syndrome by in situ hybridization using chromosome-specific alpha satellite DNA from human chromosomes 1 and 7.

T Alitalo1, H F Willard, A de la Chapelle.   

Abstract

A whole-arm translocation involving the short arm of chromosome 7 and the long arm of chromosome 1 occurs nonrandomly in myelodysplastic syndrome and acute nonlymphocytic leukemia. In situ hybridization, using alpha satellite DNA specific for the centromeric regions of chromosomes 1 (probe pSD1-1) and 7 (probe p21-4), was performed to determine the exact breakpoints of the translocation. Both probes hybridized to the centromeric region of the translocation chromosome in metaphases from two patients with myelodysplastic syndrome. Both probes hybridized with approximately equal strength to either chromosome 1 or 7 and to the 1;7 translocation chromosome, suggesting that the t(1;7) had retained the chromosome-specific alpha satellite DNA from both chromosomes. These studies permit us to propose a new description, t(1;7)(cen;cen), for this translocation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743817     DOI: 10.1159/000132718

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  3 in total

1.  Partial deletion of alpha satellite DNA associated with reduced amounts of the centromere protein CENP-B in a mitotically stable human chromosome rearrangement.

Authors:  R Wevrick; W C Earnshaw; P N Howard-Peebles; H F Willard
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

2.  Prenatal detection of short arm deletion and isochromosome 18 formation investigated by molecular techniques.

Authors:  M B Qumsiyeh; A Tomasi; M Taslimi
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

3.  Balanced reciprocal whole arm translocation t(3;9): analysis by fluorescence in situ hybridisation.

Authors:  B Blanco; F Loeza; A Carnevale
Journal:  J Med Genet       Date:  1994-01       Impact factor: 6.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.